By Richa Naidu

LONDON (Reuters] – Reckitt Benckiser, Britain’s largest baby formula company, has seen its profits rise and it is now the market leader in a $5.8billion-a-year global market. It will now be difficult to remain there.

There’s more to the story with the business being reportedly on sale.

Reckitt’s Enfamil formula has seen an increase in production since its American rival. Abbott Laboratories (NYSE:) In February, dozens of American products were recalled after parents complained about infants getting bacterial infections.

The British consumer goods giant, who increased the production of formula by 30%, said last week that more than half of US formula supply now comes from it. That’s a big increase over what was around a third prior to the crisis.

It is not common for parents to change the brands that their children like. Reckitt spokeswoman said that the company wanted to keep the customers it had gained, even though Abbott products like Similac are no longer available.

This week, the company stated that it is feeding 211,000 additional babies after this recall.

It is a high-stakes deal. Reckitt, who has been reportedly looking for a way to concentrate on his higher margin consumer and household brands such as Durex condoms to Dettol disinfectants, is rumored to have long wanted to sell its formula business. The Wall Street Journal reported that Reckitt was planning to make a new sale and it could sell for $7 billion.

The U.S. crisis might not give the U.S. a quick boost, however.

According to the U.S. Food and Drug Administration, Abbott is on track for reopening its Michigan key baby formula factory within one to two week. But Robert Califf (FDA Commissioner) told lawmakers that it would take till July before all of America’s stores were filled.

Although Abbott’s recall presents an opportunity to other companies, like Neocate maker Danone and Gerber manufacturer Nestle, Reckitt is the one that has most benefitted, since it was No.2 before the crisis.

1. April Barclays (LON) Reckitt’s 2022 organic sales forecast was increased to 4.4%, from 4.0%. This includes a 7.4% increase at the nutrition division which also includes baby formula.

Five weeks later, the company raised its forecasts by 6.0% for the group compared to 12.4% in the nutrition division.

Refinitiv says that Reckitt analysts have averaged a 4.35% increase in their earnings projections for Reckitt over the past thirty days to around 311 pence per shares.

Iain Simpson, a Barclays analyst said that Reckitt will have the greatest financial impact in the near term. Reckitt’s market share gains are likely to be lost once Abbott returns on shelves. This is the big question.

Will IT LASTEN?

The sales increase alone would lead to increased profits. Margins were further enhanced by the United States’ announcement that it would temporarily reimburse the baby formula cost for families with low incomes who are subject to government discounts in States contracting with Nestle and Reckitt.

To be the only provider of formula to low-income households under the Women, Infants, and Children (WIC), companies must bid for state contracts. They offer discounts to states in return for a “rebate” in their bids.

Effectively, the rebate is covered by government intervention. It was designed to incentivise firms to increase supplies.

Graphic: Abbott has WIC contracts with 30 U.S. states – https://graphics.reuters.com/SUPPLY-CHAIN/xmpjoxnlbvr/chart.png

Bruno Monteyne from Bernstein said, “Financially it’s great both in the top-line as well as profitability since they don’t have the need to offer a rebate for formula selling.” It will likely add at most 20-30 basis points to higher margins as long as it lasts.”

Simpson, Barclays Bank’s chief financial officer, agreed that not being bound to a WIC contract would give a boost. He estimated they had a margin of 5% in earnings before interest tax (EBIT) compared with 40-45% for non WIC contracts.

However, some analysts believe that this temporary boost may be short-lived and Reckitt might not be able retain its existing customers.

Bernstein’s Monteyne stated that Reckitt may benefit from Abbott’s reputation damage longer-term, but he also noted that the U.S. had overcome a similar backlash in just one year from a 2010 formula recall.

He stated, “There is a good precedent.”

Waverton Investment Management, Reckitt shareholder, believes that the gains in market share will be short-term.

Tineke Frikkee from Waverton, a Waverton fund manager stated that “the U.S. will be looking for other sources” to fulfill demand. Reckitt will lose its market share and Abbott will eventually get their formula on the shelves.